Cardiff Oncology Inc.
CRDF | NASDAQ
$1.37
$0 (0.00%)
At close: Sep 21, 2026, 4:00 PM ET
$1.35
-$0.02 (-1.75%)
Pre-market:
Sep 22, 2026, 9:08 AM ET
Market Data
Market Cap $105.59M
Enterprise Value $71.53M
Beta 1.46
Average Volume 1.28M
Shares Outstanding (Diluted) 68.4M
Shares Change YoY 2.81%
Institutional Ownership 35.99%
Exchange NASDAQ
ISIN US14147L1089
Price Performance
Price Change 1M 47.3%
Price Change 3M 9.6%
Price Change 6M -20.8%
Price Change YTD -48.5%
Price Change 1Y -33.8%
Price Change 3Y -14.9%
Price Change 5Y -81.4%
1M CAGR (ann.) 38.1%
1Y CAGR (ann.) -36.6%
5Y CAGR (ann.) -27.3%
All-Time CAGR -23.7%
Valuation
PE Ratio -2.28
Forward PE N/A
PEG Ratio -0.04
Forward PEG -0.42
PS Ratio 207.86
Forward PS 329.10
PB Ratio 3.98
P/FCF Ratio -2.58
P/Adj. FCF Ratio -2.29
P/OCF Ratio -2.28
EV/Sales 140.80
EV/EBIT -1.79
EV/EBITDA -1.84
EV/FCF -1.75
Earnings Yield -43.8%
FCF Yield -38.8%
Adj. FCF Yield -43.7%
Financial Health
Net Cash $34.52M
Total Debt $457K
Cash & Short-Term Investments $34.52M
Total Assets $37.33M
Current Ratio 3.30
Quick Ratio 3.30
Debt / Equity Ratio 0.02
Debt / EBITDA -0.01
Debt / FCF -0.01
OCF / Debt -89.40
Interest Coverage 0.00
Altman Z-Score -13.80
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin 100.0%
Operating Profit Margin -8320.1%
EBITDA Margin -7665.2%
Net Profit Margin -7884.1%
FCF Margin -8054.3%
Adj. FCF Margin -9082.9%
SBC / Revenue 1028.5%
SBC Impact (per share) -12.8%
Returns
Return on Assets -107.3%
Return on Equity -103.1%
Return on Invested Capital -156.6%
Return on Capital Employed -159.3%
Return on Tangible Assets -107.3%
Historical Growth (CAGR)
Revenue CAGR 3Y 7.2%
Revenue CAGR 5Y 5.2%
Revenue CAGR 10Y 3.5%
EPS CAGR 3Y 18.6%
EPS CAGR 5Y 5.2%
EPS CAGR 10Y 47.6%
FCF CAGR 3Y -11.0%
FCF CAGR 5Y -8.2%
FCF CAGR 10Y -9.9%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 15
EPS Growth Next 3Y 15.6%
Revenue Growth Next 3Y 535.3%
Earnings Date Nov 4, 2026
EPS Estimate (next Q) -$0.14
EPS Growth Est (next Q) -17.6%
Revenue Est (next Q) $81.43K
Revenue Growth Est (next Q) -32.1%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $2
Price Target Upside 46.0%
Cash Flow
Operating Cash Flow $-40.85M
Free Cash Flow $-40.92M
Adj. Free Cash Flow $-46.14M
FCF Per Share -$0.60
OCF Per Share -$0.60
OCF/S Ratio -8042.1%
Income Statement
Revenue $508K
Gross Profit $508K
Operating Income $-42.27M
EBITDA $-38.94M
Net Income $-40.05M
EPS (Diluted) -$0.60
Revenue / Employee $16.39K
Profit / Employee $-1.29M
Employees 31
Add to Watchlist
Select watchlists to add or remove CRDF